Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts (SENTICOL2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01639820 |
Recruitment Status :
Completed
First Posted : July 13, 2012
Last Update Posted : November 27, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Patients with early cervical cancer are usually treated with radical hysterectomy + pelvic lymph-node dissection. The study randomizes patients in 2 arms. The control arm is the classical surgical treatment including identification of the sentinel nodes, full pelvic lymph-node dissection and radical hysterectomy.
The experimental arm is only sentinel node identification + radical hysterectomy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Uterine Cervical Dysplasia | Procedure: identification of sentinel nodes + full pelvic lymph-node dissection Procedure: only identification of sentinel nodes (without pelvic lymph-node dissection) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 267 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Randomized Multicenter Study With Evaluation of Medico-economic Impacts |
Study Start Date : | January 2009 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Strategy A
Only identification of sentinel nodes (without pelvic lymph-node dissection)
|
Procedure: only identification of sentinel nodes (without pelvic lymph-node dissection)
only identification of sentinel nodes (without pelvic lymph-node dissection) |
Strategy B
Identification of sentinel nodes + full pelvic lymph-node dissection
|
Procedure: identification of sentinel nodes + full pelvic lymph-node dissection
identification of sentinel nodes + full pelvic lymph-node dissection |
- Number of Participants with complications observed in the 2 arms during the per and post-operative period up to 6 months [ Time Frame: 6 months after surgery ]
- Score of the questionnaire of quality of life at 30 days, 3 months and 6 months after surgery [ Time Frame: 30 days, 3 months and 6 months after surgery ]
- the costs of both studied strategies [ Time Frame: At the surgery until 6 months ]
- the detection rate of the sentinel node technique in the 2 arms [ Time Frame: Day 1 ]
- the false negative rate in the control arm [ Time Frame: Day 1 ]
- the sites of recurrence for each strategy [ Time Frame: Day 1 ]
- Number of patients without 3 years-recurrence for each strategy [ Time Frame: 3 years after surgery ]
- Number of patient treated by radio chemotherapy because of the presence of micrometastases in the sentinel node [ Time Frame: 30 days, 3 months and 6 months after surgery ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women 18 years of age or older,
- Absence of contraindication to laparoscopy,
- Uterine cervical carcinoma (every histological type except neuroendocrine),
- Stage IA1 with lymphatic tumor space involvement (LVSI) or IA2 diagnosed on cervical conization; or stage IA2, IB1 or IIA detected by clinical examination, confirmed by biopsy and measured by the MRI, the highest diameter being lower to 4 cm (a preoperative brachytherapy is allowed for tumors 2 to 4 cm in diameter),
- Negative pregnancy test for women able to procreate,
- Having the French National Social Security
- Signed informed consent
Exclusion Criteria:
- Neuroendocrine carcinoma,
- In situ carcinoma or stage IA1 without LVSI,
- Maximal tumoral diameter measured by MRI more than 4 cm,
- Stage IB1 by "down-staging",
- Stage IB2, IIB to IVB, including those who had a response to neoadjuvant treatment (chemotherapy or RT + chemotherapy) ,
- Presence of distant metastases,
- Progression of the cervical cancer or recurrence,
- History of pelvic lymphadenectomy,
- Other cancer diagnosed during the course of treatment,
- Contraindication to the injected products : allergy known to Patent Blue or rhenium sulfide,
- History of severe allergy (history of Quincke's edema, anaphylactic shock),
- Patient who does not understand, speak or write the French language,
- Pregnant woman

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01639820
France | |
Service de Gynécologie, Hôpital Femme Mère Enfant | |
Bron, France, 69677 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Hospices Civils de Lyon |
ClinicalTrials.gov Identifier: | NCT01639820 |
Other Study ID Numbers: |
2008.515 |
First Posted: | July 13, 2012 Key Record Dates |
Last Update Posted: | November 27, 2018 |
Last Verified: | December 2011 |
Cervical cancer early stage carcinoma FIGO IA1 IA2 IB1 IIA sentinel lymph node biopsy |
pelvic lymphadenectomy Surgery of uterine cervical carcinoma medico economic impact quality of life |
Uterine Cervical Neoplasms Uterine Cervical Dysplasia Cervical Intraepithelial Neoplasia Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms |
Uterine Cervical Diseases Uterine Diseases Precancerous Conditions Carcinoma in Situ Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |